Either up-regulation of miRNA-142–3p or downregulation of IRAK1 appears to be able to reduce production of NF-κB and pro-inflammation cytokines (IL-1β, IL-6) in cardiomyocytes [69], which could become potential pharmaceutical targets to treat patients with MI. The gene discussed is IRAK1; the disease is myocardial infarction.